WFRF:(Wick L.)
Search: WFRF:(Wick L.) > Upfront bevacizumab...
- 28 of 72
- Previous record
- Next record
- To hitlist
Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy : an exploratory analysis of AVAglio
- Chinot, Olivier L. (author)
- Nishikawa, Ryo (author)
- Mason, Warren (author)
- show more...
- Saran, Frank (author)
- Cloughesy, Timothy (author)
- Garcia, Josep (author)
- Revil, Cedric (author)
- Abrey, Lauren (author)
- Wick, Wolfgang (author)
- show less...
- (creator_code:org_t)
- 2016-03-22
- 2016
- English.
- In: Neuro-Oncology. - : Oxford University Press. - 1522-8517 .- 1523-5866. ; 18:9, s. 1313-1318
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Background: In this post-hoc, exploratory analysis, we examined outcomes for patients enrolled in the AVAglio trial of front-line bevacizumab or placebo plus radiotherapy/temozolomide who received only a single line of therapy. Methods: Patients with newly diagnosed glioblastoma received protocol-defined treatment until progressive disease (PD). Co-primary endpoints were investigator-assessed progression-free survival (PFS) and overall survival (OS). After confirmed PD, patients were treated at the investigators' discretion. PFS/OS were assessed in patients with a PFS event who did not receive post-PD therapy (Group 1) and patients with a PFS event who received post-PD therapy plus patients who did not have a PFS event at the final data cutoff (Group 2). Kaplan-Meier methodology was used. A multivariate Cox proportional hazards model for known prognostic variables was generated. Results: Baseline characteristics were balanced. In patients with a PFS event who did not receive post-PD therapy (Group 1; n = 225 [24.4% of the intent-to-treat population]), the addition of bevacizumab to radiotherapy/temozolomide resulted in a 3.6-month extension in both median PFS (hazard ratio [HR]: 0.62, P =.0016) and median OS (HR: 0.67, P =.0102). Multivariate analyses supported this OS benefit (HR: 0.66). In the remaining patients (Group 2; n = 696), a 5.2-month PFS extension was observed in bevacizumab-treated patients (HR: 0.61, P<.0001); OS was comparable between the treatment arms (HR: 0.88, P =.1502). No significant differences in safety were observed between the 2 groups. Conclusion: This exploratory analysis suggests that the addition of bevacizumab to standard glioblastoma treatment prolongs PFS and OS for patients with PD who receive only one line of therapy.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Keyword
- bevacizumab
- crossover
- glioblastoma
- newly diagnosed
- overall survival
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Neuro-Oncology (Search for host publication in LIBRIS)
To the university's database
- 28 of 72
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Chinot, Olivier ...
- Nishikawa, Ryo
- Mason, Warren
- Henriksson, Roge ...
- Saran, Frank
- Cloughesy, Timot ...
- show more...
- Garcia, Josep
- Revil, Cedric
- Abrey, Lauren
- Wick, Wolfgang
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Neurology
- Articles in the publication
- Neuro-Oncology
- By the university
- Umeå University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
